Publications by authors named "F Francesco Santini"
Ocular surface disease index in Graves' orbitopathy: a cross-sectional study.
Maria Novella Maglionico Giulia Lanzolla Michele Figus Giada Cosentino Simone Comi Ferruccio Santini
Front Endocrinol (Lausanne)
December 2024
Introduction: Graves' Orbitopathy (GO) is an autoimmune disorder characterized by inflammation of orbital tissues, leading to various ocular manifestations, including ocular surface disease. This cross-sectional study aimed to assess the presence of ocular surface disease using the Ocular Surface Disease Index (OSDI) in patients with Graves' disease (GD) and moderate-to-severe active GO compared to those with GD and mild non-active GO. Additionally, we aimed to investigate the correlation between ocular surface disease and the eye features of GO.
View Article and Find Full Text PDFArticle Synopsis
- * A network meta-analysis of various studies found that coronary artery bypass grafting (CABG) had the lowest late mortality rate, while the combination of subvalvular repair and annuloplasty showed promising results for reducing early death and hospital readmissions.
- * Although the combination treatment displayed potential benefits, the authors emphasize the need for more research to confirm these findings and ensure proper assessment of outcomes.
Article Synopsis
- The study explores the genetic and epigenetic factors involved in the development of Graves' orbitopathy (GO), highlighting that both sex and racial differences indicate a genetic influence on the disease.* -
- Research shows that while no specific genes have been linked to an increased risk of GO, variations in gene expression and DNA methylation patterns observed in orbital fibroblasts suggest an epigenetic component in its pathogenesis.* -
- The findings suggest that initial autoimmune triggers may lead to long-lasting changes in gene expression, contributing to the persistence and development of GO, although further examination of histone modifications is needed.*
Article Synopsis
- Sirolimus was found to help people with Graves' orbitopathy (a condition that affects the eyes) more than another medicine called methylprednisolone at the 24-week mark.
- In the study, 40 patients were treated, and researchers looked at how they felt and their eye symptoms over 48 weeks.
- While sirolimus showed better results at 24 weeks, both medicines had similar outcomes at 48 weeks, suggesting that longer treatment might be needed for better results.